Hosted on MSN2mon
FDA Breakthrough Therapy Designation Granted For Promising Rectal Cancer Drug
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab (brand name Jemperli) that has so far shown a 100 percent clinical ...
Nasdaq20d
LIXTE Biotechnology Teams Up with Lurie Cancer Center to Initiate Clinical Trial of LB-100 and GSK’s Dostarlimab for Ovarian Clear Cell Cancer
Lurie Cancer Center initiates trial combining LIXTE's LB-100 and GSK's Dostarlimab for ovarian clear cell cancer treatment. LIXTE Biotechnology Holdings, Inc. has announced that the Robert H.